The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
- ByBenzinga-
Here's a roundup of top developments in ...Full story available on Benzinga.com
Symbol | Exchange | Currency |
|---|
Here's a roundup of top developments in ...Full story available on Benzinga.com
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced positive top-line results from the human abuse potential (HAP) study with REL-1017 for major depressive disorder...
Relmada Therapeutics Inc (NASDAQ: RLMD) has acquired the development and commercial rights to novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories,...
Zoetis Inc (NYSE:ZTS). ZTS posted second-quarter 2021 adjusted earnings of $1.19 per share (excluding one-time items), which were up from the year-ago quarter’s earnings of...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 148.69 | 150.18 | 148.64 | -0.79 | -0.53% | 58.52M | NASDAQ | |||
| 324.61 | 329.63 | 321.11 | -17.27 | -5.05% | 34.95M | NASDAQ | |||
| 2,751.30 | 2,811.70 | 2,721.10 | -86.4 | -3.04% | 2.51M | NASDAQ | |||
| 55.14 | 60.78 | 55.03 | -19.97 | -26.59% | 153.83M | NYSE | |||
| 227.26 | 231.30 | 225.61 | +0.34 | +0.15% | 24.65M | NASDAQ | |||
| 127.88 | 130.25 | 126.61 | -0.45 | -0.35% | 11.54M | NYSE | |||
| 49.46 | 50.55 | 49.14 | -6.54 | -11.68% | 108.40M | NASDAQ | |||
| 43.16 | 43.19 | 42.63 | +0.30 | +0.70% | 17.15M | NYSE | |||
| 240.40 | 246.66 | 239.75 | -2.81 | -1.16% | 23.60M | NASDAQ | |||
| 664.78 | 665.46 | 651.81 | +11.62 | +1.78% | 6.02M | NASDAQ | |||
| 10.43 | 10.475 | 10.25 | +0.100 | +0.97% | 107.55K | NYSE | |||
| 169.80 | 179.49 | 167.80 | -11.91 | -6.55% | 2.76M | NYSE | |||
| 177.70 | 182.09 | 175.81 | +0.28 | +0.16% | 17.60M | NYSE | |||
| 183.52 | 187.15 | 182.88 | -3.57 | -1.91% | 1.94M | NASDAQ | |||
| 36.60 | 37.67 | 35.96 | -2.64 | -6.73% | 45.83M | NYSE |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.